[go: up one dir, main page]

EP0452447A1 - Irreversible, reduzierte bombesinantagonisten - Google Patents

Irreversible, reduzierte bombesinantagonisten

Info

Publication number
EP0452447A1
EP0452447A1 EP90915774A EP90915774A EP0452447A1 EP 0452447 A1 EP0452447 A1 EP 0452447A1 EP 90915774 A EP90915774 A EP 90915774A EP 90915774 A EP90915774 A EP 90915774A EP 0452447 A1 EP0452447 A1 EP 0452447A1
Authority
EP
European Patent Office
Prior art keywords
gly
residue
leu
ala
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP90915774A
Other languages
English (en)
French (fr)
Inventor
Roberto De Castiglione
Luigia Gozzini
Fabio Corradi
Marina Ciomei
Isabella Molinari
Cristina Franzetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898925024A external-priority patent/GB8925024D0/en
Priority claimed from GB909006413A external-priority patent/GB9006413D0/en
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Publication of EP0452447A1 publication Critical patent/EP0452447A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to peptide derivatives, to pharmaceutical compositions containing them, to processes for their preparation, and to their application as therapeutic agents.
  • AA amino acid
  • Ac acetyl
  • AcOEt ethylacetate
  • BBS bombesin
  • Boc t-butoxycarbonyl
  • BuOH n-butyl alcohol
  • BOP benzotriazolyloxy-tris[dimethylamino]phosphonium hexafluorophosphate
  • DMAP 4-dimethylaminopyridine
  • DMF freshly distilled dimethylformamide
  • DMSO dimethylsulfoxide
  • Dnp 2,4-di- nitrophenyl
  • EGF epidermal growth factor
  • EtOH ethyl alcohol
  • FAB epidermal growth factor
  • EtOH
  • the invention provides a peptide of the formula I:
  • R represents a group of the formula
  • CH 2 CBrCO- (either cis or trans isomers);
  • CH 2 -CH-CH 2 -CO-; CH C-CO-; ClCH 2 CH 2 CH 2 N(NO)CO-;
  • A represents a valence bond, or a Gly, Leu-Gly, Arg-Leu-Gly, or
  • B represents a valence bond or a Asn, Thr or phe residue
  • C represents a Gin or His residue
  • X represents a Gly or ala residue
  • Y represents a valence bond, or a His(R 3 ), his(R 3 ), Phe, phe, Ser, ser, Ala or ala residue;
  • T represents a valence bond, or a Leu, leu, Phe or phe residue
  • W represents a group of the formula OR 2 , NH 2 , NH(CH 2 ) 4 CH 3 ,
  • R 1 represents a hydrogen atom, a Boc group or an acyl group having from 1 to 11 carbon atoms.
  • R 2 represents a hydrogen atom, a linear or branched alyphatic chain having from 1 to 11 carbon atoms, a benzyl or a phenyl group.
  • Preferred alyphatic chains which R 2 may represent include methyl, ethyl, n-propyl-, iso-propyl, n-butyl and iso-butyl groups.
  • R 3 represents a hydrogen atom or a Tos, Dnp or Bzl group
  • R 4 represents NH 2 , NH-NH 2 or OR 2 .
  • one or more peptide bonds are replaced by reduced peptide bonds (CH 2 NH).
  • Preferred acyl group which R 1 may represent are aliphatic acyl group such as acetyl, formyl, propionyl and butirryl or aromatic such as benzoyl optionally substituted by nitro, methoxy, amino group or halogen atoms.
  • R represents pMel or Cab
  • R 1 represents hydrogen atom, Boc or acetyl group
  • A represents a valence bond
  • B represents a valence bond or phe residue
  • C represents a Gin residue
  • X represents a His (Dnp), His or Gly residue most preferably Gly
  • Y represents a valence bond
  • T represents a Leu residue
  • W represents a group of the formula Leu-NH 2 or Nle-NH 2
  • the reduced peptide bond (CH 2 NH) is that between T and W. Salts of these peptides with pharmaceutically acceptable acids are within the scope of the invention.
  • Such acid addition salts can be derived from a variety of inorganic and organic acids such as sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, nitric, sulfamic, citric, lactic, pyruvic, oxalic, maleic, succinic, tartaric, cinnamic, acetic, trifluoracetic, benzoic, salicylic, gluconic, ascorbic and related acids.
  • inorganic and organic acids such as sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, nitric, sulfamic, citric, lactic, pyruvic, oxalic, maleic, succinic, tartaric, cinnamic, acetic, trifluoracetic, benzoic, salicylic, gluconic, ascorbic and related acids.
  • the synthesis of the peptides of the invention may be accomplished by classical solution methods.
  • the synthesis consists essentially of appropriate successive condensations of protected amino acids or peptides. The condensations are carried out so that the resulting peptides have the desired sequence of amino acid residues.
  • amino acids and peptides which can be condensed according to methods known in peptide chemistry, have the amino and carboxyl groups, not involved in peptide bond formation, blocked by suitable protecting groups capable of being removed by acid or alkali treatment or by hydrogenolysis.
  • the following protective groups may, for example, be employed: benzyloxycarbonyl, t-butoxycarbonyl, trityl, formyl, trifluoracetyl, o-nitrophenylsulphenyl, 4-methyloxybenzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, 3,5-dimethoxy- ⁇ - ⁇ '-dimethylbenzyloxycarbonyl or methylsulphonylethoxycarbonyl.
  • the following protective groups may, for example, be employed: methyl, ethyl, t-butyl, benzyl, p-nitrobenzyl or fluorenylmethyl, amide, hydrazide, t-butoxycarbonyl hydrazide or benzyloxycarbonyl hydrazide.
  • the hydroxy functions of hydroxy amino acids and the imino function of histidine may be protected by suitable protecting groups (throughout all the synthesis or only during a few steps) or may be unprotected.
  • the following protective groups may, for example, be employed; t-butyl, benzyl, acetyl.
  • the following groups may, for example, be used: 2,4-dinitrophenyl, tosyl, benzyl.
  • De-protecting reactions are carried out according to methods known per se in peptide chemistry.
  • the condensation between an amino group of one molecule and a carboxyl group of another molecule to form the peptidic linkage may be carried out through an activated acyl-derivative such as a mixed anhydride, an azide or an activated ester, or by direct condensation between a free amino group and a free carboxyl group, in the presence of a condensing agent such as dicyclohexylcarbodiimide, alone or together with a racemization preventing agent, such as N-hydroxysuccinimide or 1-hydroxybenzotriazole, or together with an activating agent such as 4-dimethylamino-pyridine.
  • the condensation may be carried out in a solvent such as dimethylformamide, dimethylacetamide, pyridine, acetonitrile, tetrahydrofuran or N-methyl-2-pyrrolidone.
  • the formation of a reduced peptide bond is accomplished by condensation of an N-protected amino acid aldehyde with a C-protected amino acid or peptide in the presence of a reducing agent, such as NaBH 3 CN.
  • the aldehyde is usually obtained by condensing an N-protected amino acid with N,O-dimethylhydroxylamine, and reducing the resulting amide with a suitable reducing agent, such as LiAlH 4 .
  • the reaction temperature may be from -30°C to room temperature.
  • the reaction time is generally from 1 to 120 hours.
  • the scheme of synthesis, the protecting groups and condensing agents are selected so as to avoid the risk of racemization.
  • the peptides of the present invention are endowed with potent antagonism versus "in vitro” and "in vivo” effects induced by bombesin, such as contraction of smooth musculature, modification of behaviour of central origin and mitogenesis.
  • Bombesin is a tetradecapeptide of formula Glp-Gln-Arg-Leu- Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 , originally isolated from the skin of a frog.
  • the biological activity resides in the C-terminal part of the molecule: BBS(6-14)nonapeptide is as active as the parent compound.
  • the human counterpart of bombesin is a 27 amino acid peptide, known as gastrin-releasing peptide (h-GRP). Bombesin and bombesin-like peptides display a number of biological activities (J.H.
  • the compounds of the present invention due to the alkylating moiety, display greater receptor affinity than the parent peptides, and behave as receptor antagonists either when given in combination with bombesin or when administered 24 hours before bombesin challenge. In addition, owing to the presence of reduced peptide bonds, water solubility and, in many cases, also antagonistic properties are increased.
  • the peptides of the formula I therefore, find application in the therapy of human neoplasms which are modulated in their growth and progression by peptides of the GRP family, either directly or in concert with other growth factors.
  • alkylating analogues can be used in the management of the clinical symptoms associates with these deseases and due to hypersecretion of GRP-like peptides.
  • the compounds of the invention can be administered by the usual routes, for example, parenterally, e.g. by intravenous injection or infusion, or by intramuscular, subcutaneous, intracavity and intranasal administration.
  • the dosage depends on the age, weight and condition of the patient and on the administration route.
  • the toxicity of the peptides of the present invention is quite negligible.
  • the invention also provides pharmaceutical compositions containing a compound of formula (I) as the active substance, in association with one or more pharmaceutically acceptable excipients.
  • compositions of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
  • solutions for intravenous injection or infusion may contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile aqueous isotonic saline solutions.
  • Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols (e.g., propylene glycol) and, if desired, a suitable amount of lidocaine hydrochloride.
  • neuroendocrine neoplasms such as small cell lung carcinoma and prostatic carcinoma
  • a method of treating neuroendocrine neoplasms comprising administering to the said patients a composition of the invention.
  • B KH 2 PO 4 20 mM, pH 3.5/acetonitrile 3/7 by volume.
  • the elution was programmed with a linear gradient from 60% to 90% B over a period of 20 min (System A) or from 30 to 70% B over a period of 15 min (System B), and then isocratically for 15 min, with a flow rate of 1 ml/min.
  • peptides were characterized by their retention time (RT).
  • reaction mixture was kept for 60 min at -12°C, then for 30 min at 0°C.
  • the solvent was removed in vacuo and the residue was dissolved in AcOEt, washed with 5% NaHCO 3 and then brine to neutrality. After drying over Na 2 SO 4 , the solvent was evaporated and the oily residue purified by flash-chromatography on silica gel, eluting with AcOEt containing increasing amount of MeOH (from 0.5% to 10%).
  • the product was recovered by evaporation of the solvents and trituration with Et 2 O: 1.23 g (70.7% yield) of compound Im were obtained: m.p. 70°C (mod.) - 90°C (dec); FD-MS: m/z 651 (100, MH + ) ; Rf c 0.57; RT A 12.0.
  • Boc-pMel-OSu [prepared extemporaneously from 259 mg (0.64 mmol) of Boc-pMel-OH (see our UK Pat. Appl. No 8906000.9), 77 mg (0.67 mmol) of HOSu and 132 mg (0.64 mmol) of DCC in 5 ml of DMF] were added dropwise to a cooled solution (0°C) of 500 mg (0.43 mmol) of H-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu ⁇ (CH 2 NH) Met-NH 2 ⁇ 2 H HCl (Ip) and 0.096 ml (0.87 mmol) of NMM in 10 ml of DMF.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
EP90915774A 1989-11-06 1990-11-02 Irreversible, reduzierte bombesinantagonisten Ceased EP0452447A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898925024A GB8925024D0 (en) 1989-11-06 1989-11-06 Reduced irreversible bombesin antagonists
GB8925024 1989-11-06
GB9006413 1990-03-22
GB909006413A GB9006413D0 (en) 1990-03-22 1990-03-22 Reduced irreversible bombesin antagonists

Publications (1)

Publication Number Publication Date
EP0452447A1 true EP0452447A1 (de) 1991-10-23

Family

ID=26296160

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90915774A Ceased EP0452447A1 (de) 1989-11-06 1990-11-02 Irreversible, reduzierte bombesinantagonisten

Country Status (9)

Country Link
EP (1) EP0452447A1 (de)
JP (1) JPH04502629A (de)
KR (1) KR920701242A (de)
AU (1) AU6610390A (de)
CA (1) CA2045494A1 (de)
HU (1) HUT58763A (de)
IE (1) IE903958A1 (de)
IL (1) IL96216A0 (de)
WO (1) WO1991006563A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834433A (en) * 1990-07-26 1998-11-10 Merrell Pharmaceuticals Inc. Compounds and pharmaceutical uses of peptides of bombesin and GRP
JP3350701B2 (ja) * 1991-05-23 2002-11-25 メレルダウファーマスーティカルズ インコーポレイテッド ボンベシン類似体類
JPH07505865A (ja) * 1992-02-07 1995-06-29 メレルダウファーマスーティカルズ　インコーポレイテッド ボンベシンのフェニルアラニン類似体類
MXPA05011233A (es) 2003-04-22 2005-12-14 Conseils De Rech S Et D Aplica Vectores peptidicos.
EP3018138A1 (de) * 2010-01-25 2016-05-11 Cornell University Aromatische-kationische peptide und verwendungen davon
EP2900279B1 (de) 2012-09-25 2019-08-14 Advanced Accelerator Applications USA, Inc. Grpr-antagonisten für nachweis, diagnose und behandlung von grpr-positivem krebs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
GB8808768D0 (en) * 1988-04-14 1988-05-18 Erba Carlo Spa Peptide ligands for bombesin receptors
GR1000608B (el) * 1988-07-21 1992-08-31 Erba Carlo Spa Μεθοδος για την παρασκευη ανταγωνιστων bombesin.
JP2919889B2 (ja) * 1988-10-14 1999-07-19 アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド 治療用ペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9106563A1 *

Also Published As

Publication number Publication date
IL96216A0 (en) 1991-08-16
KR920701242A (ko) 1992-08-11
IE903958A1 (en) 1991-05-08
AU6610390A (en) 1991-05-31
CA2045494A1 (en) 1991-05-07
HUT58763A (en) 1992-03-30
JPH04502629A (ja) 1992-05-14
WO1991006563A1 (en) 1991-05-16
HU912604D0 (en) 1992-01-28

Similar Documents

Publication Publication Date Title
FI104252B (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidien kemialliseksi syntetisoimiseksi kiinteässä faasissa
JP2514518B2 (ja) ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤
US20060281685A1 (en) Methods of treatment using novel lhrh antagonists having improved solubility properties
CA2097192C (en) Bombesin antagonists
US5413990A (en) N-terminus modified analogs of LHRH
EP0380623B1 (de) Irreversible peptidliganden für bombesinrezeptoren
US5620959A (en) Bombesin antagonists
EP0101929B1 (de) Diester von Polypeptiden, ihre Herstellung und Verwendung
EP0339193B1 (de) Peptidliganden für Bombesin-Rezeptoren
EP0452447A1 (de) Irreversible, reduzierte bombesinantagonisten
AU653544B2 (en) Bombesin antagonists
AU630715B2 (en) Irreversible bombesin antagonists
EP2198878A1 (de) Polypeptide Bombesinantagonisten
KR0142195B1 (ko) 고나도리베린의 경쟁적 길항제
RU2088592C1 (ru) Терапевтические пептиды или их фармацевтически приемлемые соли
PT95779A (pt) Processo para a preparacao de derivados peptidicos antagonistas de bombesina irreversivel reduzida
FUNAKOSHI et al. Studies on Peptides. CL. Syntheses of [D-His2]-Analogs of Enkephalin and Adrenorphin and Several [D-Arg2] enkephalin Analogs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19911022

17Q First examination report despatched

Effective date: 19940316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19950522